Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases.

ABSTRACT:

Aims

Rituximab is a chimeric IgG-1 monoclonal antibody that depletes B cells, aiding in the treatment of several conditions including autoimmune diseases. It is not licensed for use in children. This study aimed to quantify the B cell-related pharmacodynamics of rituximab in children with autoimmune disease.

Methods

Routine electronic health record data were collected at a large paediatric tertiary hospital in London, UK. Dosing protocols were either 2 × 750 mg/m² intravenous infusions of rituximab on days 1 and 15, or 4 × 375 mg/m² infusions on days 1, 8, 15 and 22. Rituximab pharmacokinetics (PK) were not measured but CD19+ lymphocyte counts were taken before and after rituximab treatment. A dose-response model was constructed describing the life cycl

SUBMITTER: Pan S 

PROVIDER: S-EPMC6624401 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature